A person’s genetic profile may affect the response to mental health medications such as Amitriptyline. In neuropsychiatric disorders, when symptoms such as suicidal ideation, hallucinations, and mania are common, finding effective psychotropic medication in a timely manner is crucial. The pharmacogenomic (PGx) mental health panel provides a comprehensive and accurate investigation into drug-gene and drug-drug interactions for optimal treatment plans.
While neuropsychiatric medications are highly prescribed (about 40 million Americans), the effectiveness of these medications is critically low. Over half of psychotropic medications are inaccurately prescribed, and a large reason for this is that only 20% of the population displays the genotype for being a good metabolizer of most drugs on the market. Serotonin reuptake inhibitors (SSRI) are the most prescribed psychotropics for neuropsychiatric disorders, but research has shown that up to 30% of patients do not respond to SSRI. By individualizing medication tailored to a patient’s specific genome, providers can make accurate predictions on patient responses.